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Antiviralant cause of non-bacterial epidemic gastroenteritis, but no speciﬁc antiviral
therapies are available. We investigated the inhibitory effect of phosphorodiamidiate morpholino oligomers
(PMOs) targeted against norovirus sequences. A panel of peptide-conjugated PMOs (PPMOs) speciﬁc for the
murine norovirus (MNV) genome was developed, and two PPMO compounds directed against the ﬁrst AUG
of the ORF1 coding sequence near the 5′-end of the genome proved effective in inhibiting MNV replication in
cells. A consensus PPMO (designated Noro 1.1), designed to target the corresponding region of several diverse
human norovirus genotypes, decreased the efﬁciency of protein translation in a cell-free luciferase reporter
assay and inhibited Norwalk virus protein expression in replicon-bearing cells. Our data suggest that PPMOs
directed against the relatively conserved 5′-end of the norovirus genome may show broad antiviral activity
against this genetically diverse group of viruses.
Published by Elsevier Inc.Introduction
Noroviruses are the most important cause of non-bacterial
epidemic gastroenteritis in all age groups, and are the second most
important cause of sporadic endemic diarrhea in infants and young
children after rotaviruses (Glass et al., 2000; Green, 2007). Currently,
there are no vaccines or speciﬁc antiviral therapies for the control of
norovirus disease (Green, 2007). Noroviruses belong to the family
Caliciviridae, which consists of four genera: Norovirus, Sapovirus, Ve-
sivirus and Lagovirus. These 27–35 nm, non-enveloped viruses have
single-stranded, positive-sense RNA genomes. Norovirus genomes are
organized into three open reading frames (ORFs). The 5′ terminal ORF1
encodes a large polyprotein that is processed into mature nonstruc-
tural proteins (Green, 2007). ORF2 encodes the major capsid protein,
VP1, and the 3′ terminal ORF3 encodes aminor structural protein, VP2.
The genus Norovirus is divided into ﬁve different genogroups,
designated GI through GV. Genogroups I, II, and IV, which include
human noroviruses, are further subdivided into several genotypes
based on the similarities of the capsid (ORF2) gene (Zheng et al.,
2006). Noroviruses have highly variable genomes (up to 43%nc.nucleotide divergence between genogroups), with over 100 distinct
viruses identiﬁed to date. The 5′-end sequence of the virus is one of
the most conserved regions among norovirus genomes. Like other
caliciviruses, the 5′-end of the norovirus genome shares sequence
similarity with the 5′-end of the viral subgenomic RNA that maps near
the beginning of ORF2 (Green, 2007).
Vaccine development has been impeded by the lack of a cell culture
system for the propagation of human noroviruses. The absence of in
vitro propagation techniques has been compensated for somewhat by
the availability of recombinant virus-like particles (VLPs) produced by
the expression of VP1 in the baculovirus expression system (Bertolotti-
Ciarlet et al., 2003). Norovirus VLPs have served as antigens for the
study of norovirus immunity, and as a vaccine candidate (Estes et al.,
2000). An alternative approach to the study of norovirus RNA
replication was established when a human norovirus replicon-bearing
cell line was created by transfecting a plasmid containing most of the
Norwalk virus genome into mammalian cell lines (Chang et al., 2006).
These cell lines are capable of constitutively expressing the replicative
enzymes and other nonstructural proteins, allowing the study of RNA
replication andproviding aplatform for screeningantiviral compounds.
The recent discovery of mouse norovirus-1 (MNV-1) in immuno-
deﬁcient mice led to the development of the ﬁrst cell culture system
for the noroviruses (Wobus et al.) MNV shares molecular properties
Fig.1.Murine norovirus genome organization. Themurine norovirus genome is shown organized into three different open reading frames, together with the 5′- and 3′-nontranslated
regions (NTR). The murine norovirus PPMO targets are indicated in the ﬁgure (PMOs were synthesized as PPMOs). The direction of the arrow indicates the sense of the PPMO. Not
shown is ORF4, which partially overlaps ORF2 (Thackray et al., 2007).
329K. Bok et al. / Virology 380 (2008) 328–337with other noroviruses (Wobus, Thackray, and Virgin, 2006), although
various MNV strains are less divergent in their genome sequence and
therefore comprise a single genotype (Thackray et al., 2007). Analysis
of MNV genomes identiﬁed the three open reading frames character-
istic of noroviruses and vesiviruses (Fig. 1) (Wobus et al., 2006), and an
additional ORF4 that overlaps ORF2 in a different reading frame
(Thackray et al., 2007). ORF1 of MNV also encodes the nonstructural
proteins while ORFs 2 and 3 encode the two proteins present in the
viral capsid (Sosnovtsev et al., 2006). MNV-1 replication and disse-
mination in wild-type mice are limited by STAT-1 dependent inter-
ferons (Mumphrey et al., 2007). Thus, virus replication in lymph nodes
and intestinal tissue in vivo does not result in clinical disease in mice.
In vitro, MNV-1 grows efﬁciently in dendritic cells and macrophages
(Chaudhry et al., 2007; Ward et al., 2007; Wobus et al., 2004), facili-
tating studies of viral gene expression, replication, cytopathology, and
antiviral effector molecules. In addition, MNV is the only norovirus for
which a reverse genetic system has been developed (Chaudhry et al.,
2007; Ward et al., 2007).
In this study, we investigated the use of phosphorodiamidiate
morpholino oligomers (PMOs) as an inhibitor of norovirus replication.
PMOs are similar to single-stranded DNA oligonucleotides in that they
contain the same bases as DNA with a morpholine ring in place of a
deoxyribose sugar and a neutral backbone (Iversen, 2001). PMOs are
uncharged, water-soluble, and highly resistant to degradation in the
host. PMOs bind to mRNA by the Watson–Crick base-pairing, and can
reduce gene expression by the steric blockade of mRNA (Ghosh et al.,
2000; Stein et al., 1997; Summerton, 1999). To improve uptake into
cells, PMO can be conjugated to an arginine-rich cell-penetrating
peptide to produce peptide-PMO (PPMO) (Abes et al., 2006; Deas et al.,
2007; Moulton et al., 2004).
PMOs have been reported as effective inhibitors against a number
of viruses including hepatitis B and C viruses, inﬂuenza virus, picor-Table 1
PPMO compounds tested aligned to corresponding target sequence
PPMO (Target)a Sequenceb (5′-3′)
Human norovirusc 19TGACGCCATCATCATTCAC1
Noro 1.1 CGACGCCATCATCATTCAC
Murine norovirusd 32CGCAGAAGATGGCGTTGCCATCCTCATTTCAC1
PPMO A GGCGTTGCCATCCTCATTTCAC
PPMO B CGTTGCCATCCTCATTTCAC
PPMO C CGCAGAAGATGGCGTTGCCATCCTC
PPMO D GGCGTTGCCTTCTAGAATTCAC
Murine noroviruse 5064CATCCTCATTCACAAAGACTGCTG5
PPMO E CTCATTCACAAAGACTGCTG
PPMO F CATCCTCATTCACAAAGACTG
Murine noroviruse 7353TCTTTTCTTTGTGGTAGTTAGATGC7
PPMO G TTTCTTTGTGGTAGTTAGATGC
PPMO H TCTTTTCTTTGTGGTAGTTAG
FITC-PPMO FITC-GCATAATTCATAACTTAAC
a All PMOs synthesized as peptide-PMO (PPMO).
b AUG (start codon) is underlined.
c Based on prototype Hu/NoV/GI.1/Norwalk virus/1968/US, minus strand.
d Based on prototype Mu/NoV/GV/MNV1/2002/US, minus strand.
e Based on prototype Mu/NoV/GV/MNV1/2002/US, positive strand.
f N/A: not available.navirus (FMDV), coronavirus (mouse hepatitis and SARS), calicivirus
and West Nile virus (Burrer et al., 2007; Deas et al., 2007; Ge et al.,
2006; Heintges et al., 2001; Neuman et al., 2005; Smith et al., 2002;
Vagnozzi et al., 2007; Wang et al., 2001; Yang et al., 1999). The titers of
feline calicivirus (FCV), a vesivirus, were signiﬁcantly reduced in cell
culture by treatment with PMOs targeted to the upstream region of
ORF1 (Stein et al., 2001). Furthermore, this PMO was reported to be
effective in treating FCV disease in kittens (Smith et al., 2008). Because
the corresponding 5′-end sequence is relatively conserved within the
noroviruses, we hypothesized that this region might also function as a
target for inhibition of norovirus replication. We designed a panel of
PPMOs directed against selected regions of the murine norovirus
genome and in addition, developed a PPMO targeted to a 5′-end con-
sensus sequence representing several circulating human norovirus
genotypes. We used recently available assays to test the ability of the
PPMOs to inhibit viral protein synthesis and replication in their
corresponding homologous systems. Our study identiﬁed a target site
near the 5′-end of the norovirus genome that may prove useful for the
inhibition of viral translation and replication by speciﬁc PPMOs. The
application of PMOs to basic studies of norovirus replication in vitro
and in animal models might lead to the evaluation of this class of
chemical compounds as antiviral drugs for the prevention and
treatment of norovirus disease in humans.
Results
Effect of mouse norovirus PPMOs in cell culture
Prior to our main objective of identifying PPMOs that effectively
inhibited MNV-1 replication, it was necessary to ﬁrst demonstrate
that PPMO uptake into RAW 264.7 macrophages was dose responsive,
and to determine the maximum dose of each PPMO that was nontoxicLength Target
ORF1, antisense
19 nt 5′-end of NV genome
ORF1, antisense
22 nt 5′-end of MNV genome
20 nt 5′-end of MNV genome
25 nt 5′-end of MNV genome
22 nt 5′-end (no AUG)
044 ORF2, antisense
20 nt ORF2 of MNV genome
21 nt ORF2 of MNV genome
377 3′-end of ORF3, sense
22 nt 3′-end of MNV genome
21 nt 3′-end of MNV genome
19 nt N/Af
Fig. 3. PPMOs B and C inhibit MNV-1 replication in RAW264.7 cells. Each PPMO was
tested for its ability to inhibit MNV-1 replication in a PMO inhibition assay using the
highest concentration of the PPMO found to be nontoxic in RAW264.7 cells (PPMOs
A: 80 μM, PPMO B, D–G: 20 μM; PPMO C: 80 μM; PPMO H: 40 μM). Cells were treated
for 4 h with one of twelve PPMOs, then infected with 2×104 PFU (per well) of MNV-
1. Three days later, the cells were ﬁxed, stained, and the methanol-dissolved stain
was quantitated at an absorbance of 570 nm. For each PPMO assayed, controls
included PPMO-treated cells (no virus) and virus-infected cells with no PPMO
(untreated). Inhibition of MNV-1 replication is expressed as the average percent cell
lysis for each PMO, with error bars indicating standard deviations for quadruplicate
measurements.
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quantitatively measure the uptake of an FITC-labeled PPMO. Cells
incubated with 5, 10 20, 40, or 80 μM FITC-PPMOwere 1%, 5%,15% 38%,
63%, and 88% positive for ﬂuorescence, respectively. Although two
structural differences, the addition of an FITC label and the 3′ hydroxyl
group, prevent a direct comparison with the test PPMOs, these results
demonstrate an efﬁcient and dose-responsive uptake of peptide-
conjugated PMOs into RAW264.7 macrophages.
We subsequently identiﬁed the maximal nontoxic dose of each
MNV-1 PPMO in cytotoxicity assays. All the PPMOs designed for this
study (Table 1 and Fig. 1) were nontoxic up to a concentration of 20 μM
(Fig. 2). Higher concentrations of most PPMOs induced cytotoxicity,
with the exception of PPMOs A and C, which remained nontoxic even
at concentrations of 80 μM.
The antiviral effect of each PPMO at its maximum nontoxic
concentration (see Fig. 2) was then tested (Fig. 3). Two of the PPMOs
targeting the 5′-end of MNV-1 ORF1, PPMOs B and C, inhibited virus
replication by at least 90%. The other PPMO targeting the 5′ terminus
AUG of MNV-1, PPMO A, was signiﬁcantly less inhibitory. As expected,
PPMO D presented no inhibitory effect since the sequence fragment
complimentary to the AUG had been replaced in this compound. None
of the compounds targeting ORF2, or the 3′-end demonstrated
antiviral activity (Fig. 3, MNV PPMOE through H).
Focusing on MNV-1 PPMOs B and C, we next determined the
maximal dose of MNV-1 inhibited by the PPMOs (Fig. 4). For this
screen, each antiviral compound was tested at its maximal nontoxic
concentration (20 μM for PPMO B; 80 μM for PPMO C) against
increasing concentrations of MNV-1. To control for sequence speciﬁ-
city, we used compounds E and G as negative controls. These controls,
with no demonstrable antiviral activity, were selected based on their
similarities to PPMO B or C in nucleotide length and in the presence of
a 5′ P007-(pip-PDA) tag and 3′ acetyl group. PPMO C (80 μM) inhibited
replication of up to 2×105 PFU virus. PPMO B (20 μM) completely
inhibit replication of 2×103 PFU of MNV-1. The inhibition was
sequence-speciﬁc, as the control compounds were not effective in
preventing virus replication (Fig. 4).
In order to compare the potency of PPMOs B and C, we
determined the IC50 and IC90 for each compound, using 2×104
PFU/well MNV-1, based on the above results. As shown in Fig. 5,
PPMO B was 50% effective at a dose of 5 μM, and 90% effective in
inhibiting MNV-1 replication at 20 μM. Higher concentrations of
PPMO C were required to inhibit MNV-1 replication. At a concentra-Fig. 2. The toxicity of MNV-1 PPMOs in RAW264.7 cells. RAW264.7 cells were incubated
with various concentrations of each PPMO, ranging from 1.25 to 80 μM (per ml), as
indicated, in replicates of 8. Untreated cells served as controls. Following treatment, the
viable, adherent cells were ﬁxed and stained with crystal violet. The methanol-
dissolved stain was then quantitated on an ELISA plate reader at an absorbance of
570 nm. The average absorbance of the 8 replicates was converted to % cell lysis by the
following formula: (untreated−PMO-treated / untreated) ×100. PMO toxicity is
expressed as the average percent cell lysis for measurements at each concentration,
with error bars indicating standard deviations for quadruplicate measurements.tion of 20 μM, this compound was 70% effective in inhibiting viral
replication, and was 90% effective at 40 μM. Therefore, each
compound effectively inhibited MNV-1 replication at a dose well
below its level of cellular toxicity.
Effect of Noro 1.1 PPMO on circulating human noroviruses
A relatively limited number of 5′-end sequences were available for
circulating noroviruses associated with acute illness, so we ﬁrst
analyzed the 5′-end sequences of four norovirus strains, KL724 (GII.4),
CN3050 (GII.4), CN2753 (GII.12), and NR2210 (GII.12), that wereFig. 4. Effect of MNV-1 load on the ability of PPMO B and PPMO C to inhibit virus
replication in RAW264.7 cells. To determine the highest dose of MNV-1 for which PPMO
B and PPMO C can effectively inhibit viral replication in RAW264.7 cells, the PPMO
inhibition assay was conducted with serial 10-fold dilutions of MNV-1, ranging from 20
PFU/well up to 2×105 PFU/well, as indicated. Cells were treated with 20 μM (per ml) of
PPMO B or 80 μM (perml) of PPMO C (see Fig. 3), and then infectedwith 101,102,103,104,
or 105 PFU of MNV-1. The negative control for PPMO B is PPMO E, and the negative
control for PPMO C is PPMOG. The untreated group represents cells that were incubated
with DMEM only (no PPMO) and then infected with one of the ﬁve MNV-1 doses. Each
MNV-1 dose for each PPMO was done in 8 replicates, and the average was used in the
following formula to determine % cell lysis: ([PPMO-treated]− [PPMO-treated and virus-
infected]/ [PPMO-treated])×100. Error bars indicate standard deviations for quadrupli-
cate measurements.
Fig. 6. Cell-free transcription and translation assay. (A) Plasmid map of pCiNeo
containing the luciferase gene. (B) Schematic representation of the norovirus genome
and the transcription and translation experiment. The predicted target of Noro 1.1 is
shown.
Fig. 5. Effect of concentration on the ability of PPMO B and PPMO C to inhibit MNV-1
replication in RAW264.7 cells. To determine the lowest effective concentration of
PPMO B and PPMO C capable of inhibiting MNV-1 replication in RAW264.7 cells, the
PPMO inhibition assay was conducted with various concentrations of PPMOs, ranging
from 1.25 to 80 μM (per ml), as indicated. The untreated group represents cells that
were incubated with DMEM only (no PPMO) and then infected with MNV-1 (2×104
PFU/well). The negative control for PPMO B is PPMO E, and the negative control for
PPMO C is PPMO G. Each concentration of each PPMO was tested in 8 replicates, and
the average of these replicates was used in the following formula for % cell lysis:
([PMO-treated]− [PMO-treated and virus-infected] / [PMO-treated])×100. Error bars
indicate standard deviations for quadruplicate measurements.
331K. Bok et al. / Virology 380 (2008) 328–337collected during an epidemiologic survey of hospitalized infants in the
U.S. (Zintz et al., 2005). A comparison of these new 5′-end sequences
with those available in the GenBank database showed marked
conservation with known sequences. However, noroviruses CN2753
and CN3050 represented unique 5′-end sequences. The alignment
(Table 2) was used to design a PPMO designated Noro 1.1, that would
target a consensus 5′-end sequence representing the predominant
circulating genetic clusters of noroviruses (Zintz et al., 2005).
Based on the results presented above with MNV-1 and from
previous data in the vesivirus cell culture system (Stein et al., 2001), we
examined whether the 5′-end region of the human norovirus genome
might serve as an effective target for inhibition by a PMO. The 5′-end
sequences of the CN2753 and CN3050 viruses, as well as those from
representative prototype noroviruses indicated in Table 2, were
engineered as part of a 40 nt leader sequence into a luciferase reporter
plasmid, designated pCiNeo-Luc (Fig. 6A). In addition to the naturally
occurring 5′-end sequences, we also designed three constructs
(designated laboratory variants 1–3) that incorporated varying com-
binations of the nucleotides that showed evidence for variation among
circulating norovirus strains, in order to test the speciﬁcity of the
PPMO. The 5′-endof the JenaGIII bovinenoroviruswas also included in
the analysis. We examined whether the PPMO Noro 1.1 showed anTable 2
Variation among naturally occurring and laboratory-generated norovirus 5′ ORF1 sequence
Norovirus ORF1 target name (nt)a Variant seq
Consensus sequence GUGAAUGA
PPMO Noro 1.1 [19 mer] CACTTACT
Hu/NoV/GI.1/Norwalk virus/1968/US (1) ––––––––
Hu/NoV/GI.2/Southampton/1991/UK (0) ––––––––
Hu/NoV/GI.6/WUG1/2000/JP (1) –T––––––
Hu/No.V/GII.4/Lordsdale/1993/UK (2) ––––––––
Hu/NoV/GII.12/CN2753/1998/USA (2) ––––––––
Hu/NoV/GII.4/CN3050/1998/USA (3) ––––––––
Laboratory variant 1 (4) A–––––––
Laboratory variant 2 (5) A-A–––––
Laboratory variant 3 (6) A-A–––––
Bo/NoV/GIII.1/Jena/1998/DEU (6) ––––––––
a Number of mismatches in nucleotide sequencewhen compared toNoro 1.1 PPMO sequen
at “hot spots” observed among circulating norovirus and/or at termini of the PMO–target in
b Inhibition deﬁned as N60% reduction of protein synthesis, as deﬁned by luciferase signainhibitory effect on translation of the luciferase protein under control
of each of the 5′-end leader sequences (Fig. 6B). TheNoro 1.1 compound
was added in a range of concentrations (0.01 to 83 μM) to the trans-
lation reaction, and thepercent inhibitionwas calculated bycomparing
the luciferase expression in each reaction with a nontreated control.
Fig. 7 shows the percent inhibition as measured by luciferase
expression levels in this cell-free system. PPMO Noro 1.1 at a con-s used as targets for PPMO Noro 1.1
uence Outcome of in vitro assayb
UGAUGGCGUCG
ACTACCGCAGC-5′
––––––––––A Inhibition
––––––––––– Inhibition
––––––––––– Inhibition
A–––––––––U Inhibition
G–––––––––U Inhibition
A–––U–––––U Inhibition
A–––U–––––U Inhibition
A–––U–––––U Inhibition
A–––A––––AU No inhibition
A––CUUU-A–– No inhibition
ce. Laboratory variant sequences were designed tominimize number of hydrogen bonds
teraction.
l.
Fig. 7. Protein translation inhibition by Noro 1.1 PPMO measured by a luciferase reporter assay. The inhibitory activity of Noro 1.1 against several targets (indicated in the graph)
containing sequence variations is shown. Only targets that resulted in some degree of luciferase translation inhibition are plotted compared to the bovine strainwhich represents no
inhibition of luciferase activity. These dose–response curves are representative of at least 2 independent repetitions of the protein translation inhibition experiment for each target,
carried out by different investigators in independent laboratories.
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from a reporter RNA containing an identical complementary target
sequence and in addition, inhibited all other human norovirus ORF1
constructs. The bovine norovirus target never achievedmore than 57%
inhibition by Noro 1.1 in the range of concentrations tested. Of interest,
Noro 1.1 inhibited translation of two artiﬁcial laboratory variant
targets, LabVar 1 and 2, with 4 and 5 nucleotide changes, respectively,
although less efﬁciently. The 5′-end of the GIII bovine norovirus
genome (which contains 6 nucleotide changes from the precise NoroFig. 8. Reduced norovirus protein translation by Noro 1.1 in a replicon-bearing cell line
detected by immunoﬂuorescence with polyclonal antibodies. Norovirus protease-
polymerase detection with (A) and without (B) PMO. Norovirus main capsid protein
detection with (C) and without (D) PMO. Fluorescein conjugated Noro 1.1 transfection
efﬁciency in replicon-bearing cell line with (F) and without (E) PMO.1.1 target sequence), was the only naturally occurring viral target for
which the PPMO failed to inhibit at least 80% of the luciferase
translation, evenwith concentrations greater than 80 μM. Finally, Noro
1.1 completely failed to inhibit translation of the third laboratory
variant, which contained 6 nucleotide differences (LabVar3, data not
shown).
Effect of Noro 1.1 PMO in cell culture
In order to further test the inhibitory effect of Noro 1.1 in a cellular
environment, a replicon-bearing cell line expressing Norwalk virus
proteins (HG23) was utilized. Approximately 50% of the HG23 cells
expressed Norfolk viral proteins (as observed by immunoﬂuorescence
detecting the viral capsid protein). This fact, together with the ﬁnding
that peptide-conjugated PMOs are not efﬁciently taken up by the
HG23 cells, led us to choose electroporation as an efﬁcient means to
deliver Noro 1.1 to a majority of these cells. We tested the proportion
of cells incorporating an FITC-labeled Noro 1.1 PMO following electro-
poration in order to examine the efﬁciency of the transfection method
(Fig. 8F). The majority of cells in the monolayer showed a positive
immunoﬂuorescence signal compared to the cells receiving the FITC-
Noro 1.1 PMO without electroporation (Fig. 8E). Because the replicon
cell line was constitutively expressing viral proteins, pre-treatment
with PMO was not feasible. For this reason, the highest nontoxic
concentration (16 μM) was selected for further experiments. Noro 1.1
PPMO (16 μM) was introduced into cells by electroporation, and the
cells were incubated at 37 °C for 5 days. An immunoﬂuorescence assay
was then performed with antisera speciﬁc for Norwalk virus proteins
VP1 and the RNA-dependent RNA polymerase (RdRP) to examine viral
protein synthesis. The level of VP1 expression was visibly reduced in
the presence of PMO, compared to nontreated control cells (Figs. 8B
and D). The expression of the norovirus RdRP protein was also visibly
reduced in PMO-treated replicon cells when compared to nontreated
cells (Figs. 8A and B). These results are consistent with reduced
translation of the viral proteins by Noro 1.1.
Discussion
Human noroviruses are antigenically diverse viruses that cause
an acute illness of short duration but with prominent gastrointes-
tinal clinical manifestations (Green, 2007). The presence of norovirus-
speciﬁc serum antibodies does not correlate with resistance to
subsequent norovirus infection and illness (Lindesmith et al., 2003;
Parrino et al., 1977), complicating the impetus toward the development
Table 3
Variation among 5′ ORF1 sequences of each norovirus genogroup and/or genotype available in the GenBank database
Norovirus ORF1 target name (nt)a Variant sequence Outcome (predicted) of in vitro assay
PPMO Noro 1.1 [19 mer] CACTTACTACTACCGCAGC-5′
Hu/NoV/GI.1/Norwalk virus/1968/US (1) GUGAAUGAUGAUGGCGUCA Inhibition
Hu/NoV/GI.2/Southampton/1991/UK (0) ––––––––––––––––––– Inhibition
Hu/NoV/GI.4/Chiba 407/1987/JP (0) ––––––––––––––––––– (Inhibition)
Hu/NoV/GI.5/SzUG1/1997/JP (0) ––––––––––––––––––– (Inhibition)
Hu/NoV/GI.6/WUG1/2000/JP (1) –T––––––––––––––––– Inhibition
Hu/NoV/GI ?/Otofuke/1979/JPb (1) ––––––––––––––––––A (Inhibition)
Hu/NoV/GII.1/Hawaii/1971/USA (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.2/Snow Mountain/1976/USA (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.3/SU201/1997/JP (2) ––––––––A–––––––––U (Inhibition)
Hu/No.V/GII.4/Lordsdale/1993/UK (2) ––––––––A–––––––––U Inhibition
Hu/NoV/GII.4/CN3050/1998/USA (3) ––––––––A–––U–––––U Inhibition
Hu/NoV/GII.6/SU17/1997/JP (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.8/SU25/1997/JP (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.10/Mc37/2000/THA (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.12/Hiroshima/1999/JP (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.12/CN2753/1998/USA (2) ––––––––G–––––––––U Inhibition
Hu/NoV/GII.16/Neustrelitz260/2000/DE (2) ––––––––A–––––––––U (Inhibition)
Hu/NoV/GII.?/Guangzhou/2001/CHN (2) ––––––––A–––––––––U (Inhibition)
Bo/NoV/GIII.1/Jena/1998/DEU (6) ––––––––A––CUUU-A–– No inhibition
Mu/NoV/GV/MNV-1/2002/USA (12) –––––ATGA–GAT–GCAAC (No inhibition)
Bo/NoV/BEC/NB/80/US (13) ––––T–T–ATTATAGAGAG (No inhibition)
a Number of mismatches in nucleotide sequence when compared to Noro 1.1 PPMO sequence.
b Unclassiﬁed strain.
333K. Bok et al. / Virology 380 (2008) 328–337of an efﬁcacious vaccine. Thus, novel approaches to controlling the
infection are needed. However, in their design, consideration must be
given to the fact these viruses are also genetically diverse, withmultiple
genotypes of noroviruses co-circulatingworldwide. In 2006, Zheng et al.
proposed a genomic norovirus classiﬁcation system and a strain
nomenclature that divide noroviruses into genogroups I to V, with
each genogroup further divided into genetic clusters (or genotypes)
(Zheng et al., 2006). The uncorrected pairwise distances between
genogroups are unusually large amongRNAviruses, ranging from43% to
58%. Genogroups are then further subdivided into 8 and 17 clusters for
NoVGI andNoVGII respectively (Zheng et al., 2006). This scenariomakes
the selection of an appropriate vaccine candidate, protective correlates
aside, even more challenging.
It is in this context that antisense drugs represent viable alter-
natives for prevention as well as treatment of the disease. Norovirus
diarrhea can be a life-threatening and incapacitating disease,
especially in elderly or immuno-compromised patients and in addi-
tion, appears to be important in severe diarrhea of infants and young
children, being second to the rotaviruses in this regard. Its important
role in outbreaks of non-bacterial gastroenteritis is well known
(Green, 2007). Antisense treatment, if shown to be effective clinically,
might therefore be a promising option for various groups of patients,
those with or without difﬁculties in mounting an effective immune
response.
A murine norovirus was recently described, providing the ﬁrst
isolate in the genus that can be propagated in cell culture (Wobus et al.,
2004). This model offers an opportunity to assess PMO activity in vivo,
with a well-characterized host species. The results observed with
mouse norovirus PPMOs tested in cell culture showed that two PPMOs
targeting the MNV-1 5′ AUG translational start site of ORF1 inhibited
MNV-1 replication. These data are consistent with previous PMO
studies that proposed translation inhibition as a major mechanism of
action (Ghosh et al., 2000; Stein et al., 1997; Summerton, 1999). The
failure to translate the nonstructural proteins encoded in ORF1 of the
MNV genome would result in the inability of the virus to replicate its
RNA genome. However, it is not yet understood why certain speciﬁc
PPMOs do not inhibit the virus growth (e.g. PPMOs directed against
ORF2), and we hypothesize that additional mechanisms might be
involved in the reduction of MNV infectivity beyond the inhibition of
translation. The PPMOs directed against the 5′-end of the virus mightbe alternatively interfering with the RNA secondary structure that
has been proposed to be essential for viral RNA replication
(Simmonds et al., 2008). The disruption of this speciﬁc structure by
mutagenesis of the MNV genome has been reported to decrease virus
titers by 15 to 20 fold (Simmonds et al., 2008). The observation that
PPMO A was less effective on virus replication than PPMOs B and C
was unexpected. Its sequence completely overlaps that of PPMO B,
with two additional 5′ guanine nucleotides and its length is
intermediate (22 nt) between PPMO B (20 nt) and PPMO C (25 nt).
Comparative studies of the mechanism of action of the PPMOs in this
study could provide additional insight into the design of an optimal
antisense drug.
Noro 1.1 showed a broad range of inhibition by affecting the
protein translation of genetically diverse targets. Noro 1.1 PPMO
treatment was associated with in vitro inhibition of translation
(≥80% inhibition with ≤3 μM PMO) of all norovirus targets with up to
3 nucleotide mismatches. Therefore, based on the variability of
naturally circulating 5′-end norovirus sequences found in this study
and additional sequences submitted to GenBank since the design of
this compound (which only show 3 mismatches or less compared to
Noro 1.1, Table 3), Noro 1.1 has the potential to inhibit translation of
every human norovirus genotype described so far. However, Noro 1.1
would likely not inhibit certain animal noroviruses such as MNV-1
(12 mismatches) and bovine norovirus (6 mismatches). Noro 1.1 was
a successful inhibitor of translation of the two GII.4 variants tested,
achieving 100% inhibition in both cases. This is an important
property of Noro 1.1 since GII.4 is the most commonly detected
norovirus genotype worldwide (Bull et al., 2006; Kirkwood, 2004).
These results suggest that the efﬁcacy of a single PPMO compound
targeted to the conserved 5′-end may not be affected by the marked
genetic variability of circulating noroviruses in other regions of the
genome.
Noro 1.1was also shown to be effective in our in vitro reporter assay
well below the toxic concentrations of PPMOs described in cell culture
as well as in in vivo studies (Smith et al., 2008; Vagnozzi et al., 2007).
Only 3 μM of Noro 1.1 was needed to inhibit 80% or more of the total
protein translation of representative circulating norovirus variants, as
measured in a luciferase reporter assay system. Greater concentra-
tions were needed to achieve similar inhibition rates only when
testing artiﬁcially diverse “laboratory variants” or bovine norovirus. In
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comparable to previously reported values (Patel et al., 2008). In
addition, themurine norovirus PPMO experiments showed that 20 μM
of compound, a concentration similar to that previously reported in
PMO studies, is capable of inhibiting the replication of a wide range of
virus titers, showing an antisense effect evenwhen 2×105 PFU of MNV
were in the presence of an anti 5′-end PPMO (PPMO C) (Burrer et al.,
2007; Ge et al., 2006; Patel et al., 2008).
The inhibition of protein translation by Noro 1.1 was further con-
ﬁrmed in the experiments carried out in cell culture. Noro 1.1
effectively inhibited norovirus protein translation in HG23 cells as
evidenced by immunoﬂuorescence. This effectwas observed evenafter
a 5-day incubation period with Noro 1.1 at a concentration of 16 μM
demonstrating the stability of the compound when incubated at 37 °C
for long periods of time. This stability could potentially reduce the
number of doses needed for successful treatment. The HG23 clone
expressing the Norwalk virus replicon constitutively expresses Nor-
walk virus RNA and proteins in all cells. It has been used as a screen for
antiviral agents, such as interferon alpha (Chang and George, 2007).
However, treatment of HG23 with as high as 20 units of interferon
alpha, a concentration ten times the ED50, signiﬁcantly reduced levels
of polymerase protein, yet approximately 100 copies of RNA genome
per cell were retained. With this antiviral agent, reductions in viral
polymerase levels did not directly correlate with a reduction in viral
RNA. We, too, found a signiﬁcant reduction in Norwalk proteins after
treatment of HG23withNoro 1.1, yet did not see a signiﬁcant reduction
in RNAwith this dose of PMO (data not shown). Likely, viral polymerase
at levels below the limit of detection of IF remained, and as seen with
IFNa, a reduction in viral RNAmay require higher concentrations of the
compound. How this observation relates to a natural infection awaits
cell culture methods for propagating human noroviruses. Indirect
evidence thatMNV-1PPMOsB andC effectively inhibited viral genome
replication in the context of virus infection was demonstrated by the
fact that infection of control-treated RAW264.7 cells with an m.o.i. as
low as 0.0001 (20 PFU/2×105 cells) produced 100% CPE within 3 days,
while PPMOB or C treatment signiﬁcantly inhibited CPE resulting from
1000 times this dose (m.o.i. of 0.1) during this time.
A recent study using PPMOs to inhibit the replication of feline
calicivirus (FCV), a norovirus-related virus, showed that the antiviral
effect previously observed in vitro could be translated into a clinical
application. The antiviral strategy used was similar, testing a FCV-PMO
that masked the ﬁrst AUG of the virus genome. This compound was
initially shown to reduce FCV viral titers, in a dose-dependent manner,
by 70% when 20 μM of the PMO was present in cell culture, which is
comparable to that used in our in vitro experiments. The FCV-PMOwas
then tested in vivo, administered subcutaneously to kittens during an
outbreak of FCV disease, and 80% of treated kittens (47/59) survived
severe FCV infection, compared with 10% of non-treated kittens (3/31)
(Smith et al., 2008). The dosage used to achieve these results in vivo
was estimated to be approximately 1 μM (2 mg/kg). This study impli-
cates that the current PPMO doses used with murine and human
noroviruses “in vitro” might be translated into a successful clinical
application. The use of such an antiviral compound could represent a
huge advantage to prevent and control gastroenteritis outbreaks.
While the duration of the clinical symptoms caused by norovirus is
usually short and self-limited, shedding of the virus in stool commonly
lasts for up to a month, which greatly increases the possibility of
transmission of the disease (Green, 2007). Thus, the administration of
an antiviral to sickpatients and their contactsmight prevent the spread
of the disease, especially in sensitive settings such as hospital wards,
military ships, and nursing homeswhere itmight also prevent death of
elderly patients.
Future studies include testing PPMO compounds in the MNV
mouse model. It will also be important to investigate whether escape
variants might arise under the selective pressure of a PPMO. Further
testing of PPMOs in animal models will address important questionsregarding the application of norovirus-speciﬁc PPMO drugs to the
prevention and control of disease in humans.
Materials and methods
Cells
The macrophage cell line RAW264.7 (ATCC TIB-71) was used to
propagate MNV-1. The cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) with 4 mM L-glutamine, 1.5 g/L sodium
bicarbonate, and 10% fetal bovine serum. The norovirus replicon cell
line, HG23, expressing the Norwalk virus RNA replicon, was derived
from the human liver cell line, Huh-7 (Chang et al., 2006). The replicon
cells were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM) with 10% fetal bovine serum and 0.25 mg/ml of neomycin.
Viruses and cells
Murine norovirus strain MNV-1.CW1 (Wobus et al., 2004) was
provided by Herbert W. Virgin (Washington University School of
Medicine, St. Louis, MO). The virus was received as a titered stock
(4×107 PFU/ml) and used directly in the assays in this study. The RAW
264.7 cells were obtained from American Type Culture Collection
(Manassas, VA) and maintained in Dulbecco's Modiﬁed Essential
Medium (DMEM) with 10% fetal bovine serum and antibiotics
(penicillin, 250 units/ml and streptomycin 250 μg/ml, complete
medium).
PMO sequences
NeuGene® morpholino oligomers (PMOs) were synthesized at AVI
BioPharma Inc (Corvallis, OR). The PMOs were constructed with an
arginine-rich peptide (CytoPorter™) conjugated to the 5′-end to
facilitate cellular uptake, and an acetyl group at the 3′-end (PPMO).
Table 1 shows the PPMO compounds tested in this study. Eight
different PPMOswere generated to target the 5′-end of ORF 1 or ORF2,
or the 3′-end of the MNV-1 genome (see Fig. 1). An additional
sequence-nonspeciﬁc FITC-labeled PPMOwas generated to quantitate
cellular uptake and intracellular stability of the compounds. A single
PPMO was designed to target the 5′-end of human noroviruses ORF 1
(Noro 1.1, see Table 1). Noro 1.1 was also synthesized by Gene Tools
(Philomath, OR) as a nonconjugated PMO and a ﬂuorescein-con-
jugated PMO for use in the norovirus replicon cell culture studies. All
PPMOs and PMOs were resuspended in sterile distilled water and
further diluted in DMEM to the indicated concentrations.
Cellular uptake of a FITC-labeled PPMO
A 19-residue, peptide-conjugated PMO with an additional 5′-ﬂuo-
rescein (FITC) tag was used to quantitate the uptake of PPMOs in
RAW264.7 cells. The cellswere seeded at 2×106 cells perwell of a 6-well
plate and incubated overnight at 37 °C. The following day, the cells were
rinsed twicewith DMEM, and treated with 2.5, 5, 10, 20, 40, or 80 μM of
FITC-PPMO for 4 h at 37 °C. The PPMO was removed, the cells were
rinsed twicewith plainDMEM, and the cellswere incubated in complete
medium overnight at 37 °C. The following day, the cells were harvested,
washed with BD Pharmingen stain buffer (BD Biosciences, San Diego,
CA), resuspended in 0.5 ml of stain buffer, and passed through a 40 μm
cell strainer. The samples were then acquired on a ﬂow cytometer
(FACStar Plus, Becton Dickinson) to detect FITC staining.
Mouse norovirus PPMO toxicity assay
A toxicity assay was developed in order to examine whether
treatment of RAW264.7 cells with MNV-1-speciﬁc PPMOs caused
nonspeciﬁc cytotoxic effects. RAW264.7 cells (2×105 cells/well) were
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were rinsed twice with plain DMEM and incubated for 4 h with
varying concentrations of PPMO diluted in plain DMEM. The
concentrations of each PPMO tested (in replicates of eight) were
1.25, 2.5, 5, 10, 20, 40, and 80 μM. Following incubation, the cells were
rinsed twicewith DMEM, completemediumwas added, and the plates
were incubated at 37 °C for 24 h. The following day, the plates were
rinsed twice with warm PBS, and the cells were ﬁxed with 10%
buffered formalin (Fisher Scientiﬁc, Fairlawn, NJ) overnight. The plates
were then rinsed with tap water and dried overnight. Following
staining of the cell monolayer with 0.4% crystal violet, the plates were
rinsed extensively and left to dry at room temperature. The following
day, 200 μl of 100% methanol was added per well, allowed to incubate
at room temperature for 1 h, and the methanol-dissolved stain was
transferred to the wells of a clean 96-well plate. The plates were then
read on an ELISA plate reader (EL340, Bio-Tek Instruments) at an
absorbance of 570 nm. The average absorbance of the 8 replicates was
converted to percent cell lysis by the following formula: % cell
lysis=untreated]− [PMO-treated] / [untreated]×100.
Mouse norovirus PPMO inhibition assay
Each PPMOwas tested for its ability to inhibit MNV-1 replication in
a PPMO inhibition assay using the highest concentration of the PPMO
found to be nontoxic in RAW264.7 cells (see above). Brieﬂy, 2×105
RAW264.7 cells/well were seeded into ﬂat-bottom 96-well plates. The
following day, the cells were rinsed twice with plain DMEM, and the
PPMOwas added at the desired concentration to eight replicate wells.
Following treatment with PPMO for 4 h, the cells were rinsed twice
with plain DMEM, and 50 μl of complete medium containing 2×104
PFU of MNV-1 was added to each well and allowed to incubate for 2 h
at 37 °C. The inoculum was removed, and following one rinse with
complete medium, 200 μl of complete media was added per well and
the plateswere incubated for 3 days at 37 °C. Controls included PPMO-
treated cells without virus and virus-infected cells with no PPMO
(untreated). The plates were rinsed twice with PBS, ﬁxed with 10%
buffered formalin, stained with crystal violet, and the intensity of the
methanol-dissolved stain was quantitated as above. The average
absorbance at 570 nm of the 8 replicates was converted to percent cell
lysis using the following formula: % cell lysis=([PMO-treated]− [PMO-
treated and virus-infected] / [PMO-treated])×100.
Virus dose–response in PPMO inhibition assay
The PPMO inhibition assay described above was carried out to
determine the highest dose of MNV-1 for which PPMO B and PPMO C
could effectively inhibit viral replication. Serial 10-fold dilutions of
MNV-1 (ranging from 20 PFU/well up to 2×105 PFU/well, as indicated)
were used to infect RAW264.7 cells. Brieﬂy, cells were treated with
20 μM of PPMO B or 80 μM of PPMO C, and then infected (in replicates
of eight) with one of the ﬁve doses of MNV-1. PPMO E and PPMO G
were used as negative controls. The untreated group represents cells
that were incubated with DMEM only (no PPMO) and then infected
with one of the ﬁve MNV-1 doses. Percent cell lysis was quantitated
with the following formula: % cell lysis (for each virus dose)=([PMO-
treated]− [PMO-treated and virus-infected] / [PMO-treated])×100.
PPMO dose–response in PPMO inhibition assay
A PPMO inhibition assay was carried out to determine the lowest
effective concentration of PPMO B and PPMO C capable of inhibiting
MNV-1 replication in RAW264.7 cells. The virus concentration
remained constant (2×104 PFU MNV-1 per well) while various
concentrations of PPMO B or C, ranging from 1.25 to 80 μM (in
replicates of eight)were used. The negative controlswere PPMOs E and
G. Percent cell lysis was quantitated using the following formula: % celllysis (for each PMO dose)=([PMO-treated]− [PMO-treated and virus-
infected] / [PMO-treated])×100.
Consensus sequence analysis of the 5′-end region of human norovirus
genomes
In order to design a PMO targeted to human noroviruses, available
5′-end genome sequences were aligned and examined for conserved
regions. In addition, we selected representative circulating norovirus
specimens from an epidemiological study that was conducted at three
hospital sites across the U.S. from November 1997 to December 1999
(Zintz et al., 2005) for partial genomic sequence analysis. Stool samples
were collected within 24 h of admission, frozen and sent to the Center
for Pediatric Research (Norfolk, Virginia) where they were stored at
−70 °C until screening by RT-PCR. One-hundred thirty-ﬁve children
with norovirus illness were identiﬁed and portions of the norovirus
genome were sequenced from each infecting strain to conﬁrm the
norovirus diagnosis and examine genetic diversity. Norovirus variants
(NR2210, KL724, CN2753, CN3050) representing the most divergent
phylogenetic clusters in the collection, were selected for 5′-end
sequence analysis. Brieﬂy, a 5′-end RACE kit (Roche Applied Science,
Indianapolis, IN) was used according to the manufacturer's protocols,
employing primers deduced fromrelated viruses belonging to the same
genotype as the variant (primer sequences available upon request).
Luciferase reporter assay
The ability of the PPMO Noro 1.1 to target a panel of diverse 5′-end
sequences was evaluated in an in vitro reporter assay. Brieﬂy, each
reporter plasmid was engineered to include a 5′-end sequence of
interest (summarized in Table 2) as a translational “leader” sequence
(approximately 40 nt in length) fused in frame immediately upstream
of the ﬁreﬂy luciferase gene in which the ﬁrst A of the AUG codonwas
removed. The leader sequences were synthesized as oligonucleotides
with engineered restriction enzyme sites at the 5′- and 3′-ends to
facilitate cloning into the NheI and SalI sites of the expression
plasmid, pCiNeo (Promega, Madison, WI). The expression cassette in
the vector was organized as follows: CMV promoter–intervening
intron–T7 promoter–leader sequence–luciferase gene–poly-A signal
(Fig. 6A). Each construct was veriﬁed by sequence analysis. The
resulting plasmid DNA was digested with a restriction enzyme (NotI),
puriﬁed, and RNA was transcribed from the plasmid with T7
polymerase (Megascript, Ambion, Austin, TX). The transcribed RNA
was puriﬁed and run in an agarose gel to verify quality and size. In
addition, the RNA was quantitated by UV spectroscopy and 6 nM
solutions were prepared for use in translation assays. The translation
reaction was carried out in a rabbit reticulocyte lysate (Promega,
Madison, WI). To assess the effect of the Noro 1.1 PPMO on
translation, a reaction included the following: 3 μl PPMO (ﬁnal
concentration 0.01-83 μM), 3 μl RNA (ﬁnal concentration 1 nM), 1 μl
amino acid mix, and 11 μl nuclease-treated rabbit reticulocyte lysate.
This reaction was incubated for 75 min at 37 °C and terminated by
chilling on ice. Ten microliters of this reaction was then added to 50 μl
of luciferase assay reagent (Promega, Madison, WI), mixed gently 5
times and incubated for 30 s at room temperature, after which light
emission was measured (Dynex MLX luminometer, Dynex, Chantilly,
VA). Controls for this experiment included (i) a nonspeciﬁc PMO
directed against ORF3 of vesiviruses (Stein et al., 2001), (ii) non-
treated (no PMO), and (iii) a specimen without RNA. The Noro 1.1
PPMO was assayed within a range of concentrations that were
effective and nontoxic in previous cell culture studies. Each assay was
performed at least twice and constructs were analyzed by two
independent investigators in two separate laboratories to verify
reproducibility. Percent inhibition was determined by comparing the
reduction in the ﬁreﬂy luciferase signal of different concentrations of
a speciﬁc PPMO with the signal obtained without PPMO in the well.
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The cloned cell lineHG23 expressing self-replicating norovirus RNA
(norovirus replicon) was used to test Noro 1.1 PMO activity in cell
culture (Chang et al., 2006). First, the degree of incorporation of PMO
into the replicon-bearing cell line was assayed using a ﬂuorescein
conjugatedNoro 1.1 PMO (FITC-Noro 1.1). In order to determine the best
electroporation conditions for the HG23 cell line, an optimization kit
was utilized to test several electroporation solutions combined with
different nucleofection programs (Nucleofector, Amaxa, Gaithersburg,
MD). Electroporation solution “L” combined with the nucleofection
program “A020” was selected as the best compromise between cell
viability and PMO incorporation. A range of concentrations of FITC-
Noro 1.1 (1 to 16 μM) was electroporated (Nucleofector, Amaxa,
Gaithersburg, MD) into the replicon cell line, and cell monolayerswere
observed 24 h later for ﬂuorescence to determine the toxicity and
optimal concentration of PMO. Based on this experiment, 16 μM
(maximum concentration and nontoxic) of the Noro 1.1 PMO was
electroporated into 2×106 replicon-bearing cells, which were then
seeded into 100 mm cell culture plates. The monolayers were incu-
bated for 5 days, and then ﬁxed with ice-cold methanol for analysis by
immunoﬂuorescence with antibodies raised in guinea pigs against the
Norwalk virus VP1 and polymerase proteins as previously described
(Chang et al., 2006). In order to assess the effect of such Noro 1.1
treatment on the levels of RNA in the replicon-bearing cells, the RNA
present in treated and untreated samples was quantiﬁed using a
single-step quantitative real-timeRT-PCR.One Taq-Manprobe and two
primers that speciﬁcally ampliﬁed the GI genotype (the norovirus
genotype present in the replicon cell line) were utilized (Liu and Moe,
2006). Brieﬂy, 5 μl of RNA extracted from2×106 cells/ml using a Qiagen
RNA extraction kit (Qiagen, Valencia, CA) was added to an RT-PCR mix
(Brilliant II q RT-PCR core reagent kit, Stratagene, La Jolla, CA). The
reaction conditions were as follows: 45 °C for 30min, 95 °C for 10min,
followed by 45 cycles of 95 °C for 30 s, 50 °C for 1min and 72 °C for 30 s
in an ABI 7900 HT real time detector (Applied Biosystems, Foster City,
CA). An appropriate standard curve was included in each run.
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